КРИОГЛОБУЛИНЕМИЧЕСКИЙ ВАСКУЛИТ

1. <div><p>Ferri C., Sebastiani M., Giuggioli D. et al. Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival 231 patients. Semin Arthr Rheum 2004;33(6):355-77.</p><p>Васильев В.И., Пробатова Н.А., Варламова Е.Ю. и др. Прогностическое значение смешанной моноклональной криоглобулинемии при болезни Шегрена. Тер арх 2004;8:61-80.</p><p>Brouet J., Clauvel E., Danon F. et al. Biologic and clinical significance of crioglobulins: a report of 86 cases. Amer J Med 1974;57:774-82.</p><p>Gorevic P.D., Kassab H.J., Levo Y. Mixed cryoglobulinemia: clinical aspects and longterm follow-up of 40 patients. Amer J Med 1980;69:287-308.</p><p>Monti G., Galli M., Invernizzi F. Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM 1995;88:115-26.</p><p>Rieu V., Cohen P., Andre M.H. Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. Rheumatology (Oxford) 2002;41:290-300.</p><p>Trejo O., Ramos-Casals M., Garcia-Carrasco M. Cryoglobulinemia: study of etiological factors and clinical and immunological features in 443 patients from a single center. Medicina (Baltimore) 2001;80:252-62.</p><p>Васильев В.И., Ходарев Н.В., Мач Э.С. и др. Криоглобулинемия при болезни Шегрена. Тер арх 1990;5:66-70.</p><p>Musset L., Diemert M.C., Taibi F. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992;38:798-802.</p><p>Tissot J.D., Schifferli J.A., Hochstrasser D.F. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Meth 1994;173:63-75.</p><p>Cacoub P., Costedoat-Chalumeau N.,Lidove O. Cryoglobulinemia vasculitis. Curr Opin Rheumatol 2002;14:29-35.</p><p>Tedeschi A., Barate C., Vinola E., Morra E. Crioglobulinemia. Blood Reviews 2007;21:183-200.</p><p>Deuffic-Burban S., Poynard T., Sulkowski M.S. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infection in the United States. J Viral Hepat 2007;14:107-15.</p><p>Ghany M.G., Strader D.B., Thomas D.L. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.</p><p>Васильев В.И. Болезнь Шегрена: клинико-лабораторные, иммуноморфологические проявления и прогноз: Дис. д- ра мед. наук. М., 2007.</p><p>Saadoun D., Sellam J., Ghillani-Dalbin P. Increased risk of lymphoma and death among patients with non-hepatitis C virusrelated mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8.</p><p>Константинова Н.А. Криоглобулины и патология. М.: Медицина, 1999.</p><p>Соринсон С.Н. Вирусные гепатиты. СПб.: Теза, 1997.</p><p>Alter H.J. To C or not to C: These are the question. Blood 1995;85(Suppl. 7):1681-95.</p><p>Blum H.E. Variants of hepatitis B, C and D viruses: Molecular biology and clinical significance. Digestion 1995;56(Suppl. 2):85-95.</p><p>Scagnolari C., Casato M., Bellomi F. et al. Serum Interferon (IFN)-neutrolising antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 2003;10(1):70-7.</p><p>Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21(Suppl. 2):5870-3.</p><p>Ferri C., Zignego A.L., Pileri S.A. Cryoglobulins. J Clin Pathol 2002;55:4-13.</p><p>Lamprecht P., Gause A., Gross W.L. Cryoglobulinemic vasculitis. Arthr Rheum 1999;42(12):2507-16.</p><p>Matsumori A., Matoba Y., Sasayama S. Dilated сardiomyopathy аssociated with hepatitis C virus infection. Circulation 1995;92:2519-25.</p><p>Thomsson R., Bonk S., Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of -lipoproteins and immunoglobulins. Med Microbiol Immunol 1993;182:329-47.</p><p>Анфимова М.Л., Лебедева Т.В., Ходарев Н.В. и др. Фибронектин, криоглобулинемия и иммунные комплексы при болезни Шегрена. Rus J Immunol 1996;1(Suppl. 1):29-34.</p><p>Sansonno D., Iacobelli A.R., Cornacchiulo V. et al. Immunochemical and biochemical studies of circulating immune complexes isolated from patients with acute and chronic hepatitis C virus infection. Eur J Clin Invest 1996;26(Suppl. 6):465-75.</p><p>Козловская Л.В., Гордовская Н.Б., Малышко Е.Ю. и др. Криоглобулинемическое поражение почек - особенности течения и лечение. Нефрология и диализ 2002;4(1):4-8.</p><p>Гордовская Н.Б., Козловская Л.В. Поражение почек при смешанной криоглобулинемии. Нефрология. Под ред. И.Е. Тарееевой. М.: Медицина, 2000;304-7.</p><p>Fabris M., Quartuccio L., Sacco S. et al. B-Lymphocyte stimulator (BlyS) up-regulation in mixed cryoglobulinemia syndrome and hepatitis-C virus infection. Rheumatology 2007;46:37-43.</p><p>Sene D., Limal N., Ghillani-Dalbin P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BlyS/BAFF). Rheumatology 2007;46:65-9.</p><p>Васильев В.И., Пробатова Н.А., Тупицын Н.Н. Лимфопролиферативные заболевания при болезни Шегрена. Онкогематология 2007;3:16-26.</p><p>Tzioufas A.G., Boumba D.S., Skopouli F.N. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor crossreactive idiotypes as predictive factors for the development of lymphoma in primary Sjц gren's syndrome. Arthr Rheumatol 1996;39(5):767-72.</p><p>Васильев В.И., Пробатова Н.А., Тупицин Н.Н. MALT-лимфомы при болезни Шёгрена. Тер арх 2006;1:45-52.</p><p>Мануйлова Л.С. Клинико-морфологические изменения в сосудах при болезни Шегрена: Дис. канд. мед. наук. М., 1992.</p><p>Braun G.S., Horster S., Wagner K.S. Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects. Postgrad Med J 2007;83:87-94.</p><p>Васильев В.И., Симонова М.В., Сафонова Т.Н. и др. Современные подходы к использованию глюкокортикостероидных и цитотоксических препаратов в терапии болезни Шeгрена. Совр ревматол 2008;2:39-59.</p><p>Белинин Г.Ю., Васильев В.И., Ефремов Е.Е. и др. Клиническая эффективность криоафереза у больных с криоглобулинемиями. Тромбоз, гемостаз и реология 2004;4(20):45-55.</p><p>Zignego A.L., Ferri C., Giannini C. et al. Hepatits C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996;124(1-1):31-4.</p><p>Sabry A.A., Sobh M.A., Sheeashaa H.A. et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002;17:1924-30.</p><p>Mazzaro C., Pozzato G., Moretti M. et al. Long-term effects of -interferon therapy for type II mixed cryoglobulinemia. Haematologica 1994;79:342-49.</p><p>Casato M., Agnello V., Pucillo L.P. et al. Predictors of long-term response to highdose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-73.</p><p>Mazzaro C., Zorat F., Caizzi M. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-8.</p><p>Cacoub P., Saadoun D., Limal N. Pegylate and interferon-alpha-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthr Rheum 2005;52:911-5.</p><p>Cacoub P., Delluc A., Saadoun D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-7.</p><p>Логвиненко О.А., Васильев В.И. Ритуксимаб в лечении криоглобулинемического васкулита. Науч-практич ревматол 2009;1(прил.):61-72.</p><p>Roccatello D., Baldovino S., Rossi D. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61.</p><p>Quartuccio L., Soardo G., Romano G. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatol 2006;45:842-6.</p><p>Sansonno D., de Re V., Lauletta G. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon- with an anti-CD20. Blood 2003;101(10):3818-26.</p><p>Saadoun D., Resche-Rigon M., Sene D. Rituximab combined with peg-interferonribavirin in refractory HCV-associated cryoglobulinemia vasculitis. Ann Rheum Dis 2008;67:1431-6.</p><p>Chandesris M.-O., Gayet S., Schleinitz N. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinemia. Rheumatol 2004;43:532-3.</p><p>Ferri C., Ferraccioli G., Ferrari D. Safety of antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9.</p><p>Vassilopoulos D., Calabrese L.H. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007;19:619-25</p><p>De Vita S., Quartuccio L. Rituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinemia. Rheumatology 2006;45:784-5.</p><p>Fin Zheng Jun Cai, Ahern M., Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. Rheumatology 2006;33:1197-8.</p><p>Thiel J., Peters T., Mas M.A. et al. Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinemia with pulse cyclophosphamide. Ann Rheum Dis 2002;61:838-41.</p><p>Saadoun D., Landau D.A., Calabrese L.H., Cacoub P.P. Hepatitis C-associated mixed cryoglobulinemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology 2007;46:1234-42.</p><p>Vassilopoulos D., Manolakopoulos S. Rheumatic manifestations of hepatitis. Curr Opin Rheumatol 2010;22:91-6.</p></div><br />